Stereotactic Body Radiotherapy for Metastatic Lung Cancer As Oligo-recurrence: an Analysis of 42 Cases

Overview

Journal Pulm Med

Publisher Wiley

Specialty Pulmonary Medicine

Date 2012 Oct 25

PMID 23094150

Citations 16

Authors

Wataru Takahashi

Hideomi Yamashita

Yuzuru Niibe

Kenshiro Shiraishi

Kazushige Hayakawa

Keiichi Nakagawa

Affiliations

Soon will be listed here.

Abstract

Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1-90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75-99%) and 65% (95% CI, 48-82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) <31.9 months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI ≧31.9 months (P < 0.05). The most commonly observed late effect was radiation pneumonitis. One patient had grade 4 gastrointestinal toxicity (perforation of gastric tube). No other ≧ grade 3 acute and late adverse events occurred. There were no treatment-related deaths during this study. Conclusions. In patients with ORCL, radical treatment with SBRT is safe and provides a chance for long-term survival by offering favorable local control.

Citing Articles

Oligo-Recurrence in Lung Cancer; The Most Curable State Among Advanced Disease?.

Shimada Y Cancers (Basel). 2024; 16(23).

PMID: 39682272 PMC: 11639969. DOI: 10.3390/cancers16234086.

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.

Ho C, Tsai J, Chen C, Shiah H, Chen H, Ting L Diagnostics (Basel). 2023; 13(9).

PMID: 37174988 PMC: 10177978. DOI: 10.3390/diagnostics13091597.

Modern evidence and future prospects of external body radiation therapy for lung oligometastases of breast cancer.

Wada Y, Hashimoto M Transl Cancer Res. 2022; 9(8):5077-5086.

PMID: 35117873 PMC: 8799217. DOI: 10.21037/tcr.2020.02.55.

Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers.

Aibe N, Ogino H, Teramukai S, Yamazaki H, Iwata H, Matsuo Y Adv Radiat Oncol. 2021; 6(4):100690.

PMID: 34159280 PMC: 8193372. DOI: 10.1016/j.adro.2021.100690.

Carbon-ion Radiotherapy for Colorectal Cancer.

Yamada S, Takiyama H, Isozaki Y, Shinoto M, Makishima H, Yamamoto N J Anus Rectum Colon. 2021; 5(2):113-120.

PMID: 33937550 PMC: 8084540. DOI: 10.23922/jarc.2020-082.

References

Ricardi U, Filippi A, Guarneri A, Ragona R, Mantovani C, Giglioli F . Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2011; 75(1):77-81. DOI: 10.1016/j.lungcan.2011.04.021. View

Okunieff P, Petersen A, Philip A, Milano M, Katz A, Boros L . Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006; 45(7):808-17. DOI: 10.1080/02841860600908954. View

Hill A, Kiss N, Hodgson B, Crowe T, Walsh A . Associations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients. Clin Nutr. 2010; 30(1):92-8. DOI: 10.1016/j.clnu.2010.07.015. View

Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T . Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011; 101(2):255-9. DOI: 10.1016/j.radonc.2011.05.033. View

Oh D, Ahn Y, Seo J, Shin E, Park H, Lim D . Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol. 2012; 51(5):596-602. DOI: 10.3109/0284186X.2012.681698. View

Hoff C, Grau C, Overgaard J . Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma--a prospective study. Radiother Oncol. 2012; 103(1):38-44. DOI: 10.1016/j.radonc.2012.01.011. View

Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M . Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008; 72(2):398-403. DOI: 10.1016/j.ijrobp.2008.01.002. View

Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C . Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys. 2006; 66(5):1366-9. DOI: 10.1016/j.ijrobp.2006.07.1384. View

Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Ii N . Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol. 2006; 103(2):435-8. DOI: 10.1016/j.ygyno.2006.03.034. View

10.

Niibe Y, Kuranami M, Matsunaga K, Takaya M, Kakita S, Hara T . Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res. 2009; 28(6B):3929-31. View

11.

Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues G, Ward A . Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012; 102(3):335-42. DOI: 10.1016/j.radonc.2011.12.018. View

12.

Niibe Y, Hayakawa K . Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010; 40(2):107-11. PMC: 2813545. DOI: 10.1093/jjco/hyp167. View

13.

Rusthoven K, Kavanagh B, Burri S, Chen C, Cardenes H, Chidel M . Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009; 27(10):1579-84. DOI: 10.1200/JCO.2008.19.6386. View

14.

Jabbour S, Daroui P, Moore D, Licitra E, Gabel M, Aisner J . A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis. 2012; 3(1):4-9. PMC: 3256496. DOI: 10.3978/j.issn.2072-1439.2010.12.09. View